Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 61016-61017 [2020-20943]
Download as PDF
<![CDATA[
61016
Federal Register / Vol. 85, No. 189 / Tuesday, September 29, 2020 / Notices
this notice finalizes the draft guidance
dated January 2019.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘ANDA
Submissions—Amendments and
Requests for Final Approval to
Tentatively Approved ANDAs.’’ It does
not establish any rights for any person
and is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
II. Electronic Access
Persons with access to the internet
may obtain the guidance at either
https://www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs or https://
www.regulations.gov.
Dated: September 22, 2020.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2020–21470 Filed 9–28–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice To Announce Supplemental
Award To Support Training and
Technical Assistance To Address
Clinical Workforce Development
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Announcing supplemental
award to support training and technical
assistance to address clinical workforce
development.
AGENCY:
HRSA provided supplemental
funding to Community Health Center,
Inc. (CHCI), a currently-funded National
Training and Technical Assistance
Partner (NTTAP) award recipient. CHCI
will expand training and technical
assistance (T/TA) to health centers and
HRSA-funded State and Regional
Primary Care Associations (PCAs) to
support implementation of a tool
developed for health centers to assess
and improve their readiness to engage in
health professional training programs
and address national health care
workforce shortages.
FOR FURTHER INFORMATION CONTACT:
Tracey Orloff, Director, HRSA, Strategic
Partnerships Division, Office of Quality
Improvement, at TOrloff@hrsa.gov or
(301) 443–3197.
SUPPLEMENTARY INFORMATION:
Thomas J. Engels,
Administrator.
[FR Doc. 2020–21514 Filed 9–28–20; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:14 Sep 28, 2020
Jkt 250001
Health Resources and Services
Administration
Meeting of the CDC/HRSA Advisory
Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Centers for
Disease Control and Prevention (CDC)/
HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and
Treatment (CHAC) has scheduled a
public meeting.
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
November 5, 2020, 2:00 p.m.–
5:15 p.m. Eastern Time (ET) and
November 6, 2020, 2:00 p.m.–5:15 p.m.
ET. The deadline for online registration
is 12:00 p.m. ET on November 2, 2020.
ADDRESSES: This meeting will be held
virtually. Please visit the meeting
information page to register: https://
chacfall2020.org.
FOR FURTHER INFORMATION CONTACT:
Theresa Jumento, Senior Public Health
Advisor, HIV/AIDS Bureau, HRSA, 5600
Fishers Lane, Rockville, Maryland
20857; 301–443–5807; or
CHACAdvisoryComm@hrsa.gov.
SUPPLEMENTARY INFORMATION: CHAC was
established under section 222 of the
Public Health Service Act, [42 U.S.C.
217a], as amended.
The purpose of CHAC is to advise the
Secretary, HHS; the Director, CDC; and
the Administrator, HRSA regarding
objectives, strategies, policies, and
priorities for HIV, viral hepatitis, and
other STDs; prevention and treatment
efforts including surveillance of HIV
infection, viral hepatitis, and other
STDs, and related behaviors;
epidemiologic, behavioral, health
services, and laboratory research on
HIV, viral hepatitis, and other STDs;
identification of policy issues related to
HIV/viral hepatitis/STD professional
eduction, patient healthcare delivery,
and prevention services; agency policies
about prevention of HIV, viral hepatitis
and other STDs; treatment, healthcare
delivery, and research and training;
strategic issues influencing the ability of
CDC and HRSA to fulfill their missions
of providing prevention and treatment
services; programmatic efforts to
prevent and treat HIV, viral hepatitis,
and other STDs; and support to the
agencies in their developoment of
responses to emerging health needs
related to HIV, viral hepatitis, and other
STDs.
During the November 5–6, 2020,
meeting, CHAC will discuss community
engagement activities related to the
President’s initiative on ‘‘Ending the
HIV Epidemic: A Plan for America’’ and
the COVID–19 pandemic. CHAC will
also discuss the needs and challenges of
HIV prevention and care for women.
Agenda items are subject to change as
priorities dictate. Refer to the CHAC
meeting information page for any
updated information concerning the
meeting.
While this meeting is open to the
public, advance registration is required.
Members of the public will have the
opportunity to provide comments.
Requests to offer oral comments will be
accepted in the order they are received
and may be limited as time allows.
DATES:
Recipient of the Award: Community
Health Center, Inc.
Amount of Non-Competitive Award:
$320,000.
Period of Supplemental Funding:
August 2020 to June 2022.
CFDA Number: 93.129.
Authority: Section 330(l) of the Public
Health Service Act, 42 U.S.C. 254b(l).
Justification: The National Center for
Health Workforce Analysis estimates a
shortage of over 23,000 primary care
physician positions by 2025. Residency
programs are needed for health centers
to address health care workforce
shortages that limit their ability to
deliver comprehensive, culturally
competent, high quality primary health
care services.
CHCI created the Readiness to Train
Assessment Tool (RTATTM) for health
centers to assess their own readiness to
engage in health professional training
programs and use the results to manage
their workforce shortages. Supplemental
funding is necessary to ensure timely
implementation of the RTATTM in order
to complete the data collection,
analysis, and results dissemination
needed for health centers to address
critical workforce shortages. As the
organization that developed the
RTATTM, and the only NTTAP currently
funded to provide enhanced T/TA on
clinical workforce development to
health centers, CHCI has the necessary
expertise, organizational systems, and
structure in place to immediately
expand T/TA efforts in this area.
E:\FR\FM\29SEN1.SGM
29SEN1
Federal Register / Vol. 85, No. 189 / Tuesday, September 29, 2020 / Notices
Public participants may also submit
written statements as further described
below. To submit written comments or
to request time for an oral comment at
the meeting, please register online by
12:00 p.m. ET on October 28, 2020.
Information about CHAC can be found
on the CHAC website at https://
www.cdc.gov/maso/facm/
facmCHACHSPT.html. Visit the meeting
information page for additional details
https://chacfall2020.org. Individuals
who plan to attend and need special
assistance or another reasonable
accommodation should notify Theresa
Jumento at the email address and phone
number listed above at least 10 business
days prior to the meeting.
Maria G. Button,
Director, Executive Secretariat.
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
SEP for Career Development (K99/R00 and
K12 applications).
Date: November 4, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review,
Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, 3 WFN 9th Floor, MSC
6021, Bethesda, MD 20892, (301) 827–5702,
sindhu.kizhakkemadathil@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
18:14 Sep 28, 2020
Jkt 250001
Dated: September 23, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–21497 Filed 9–28–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meetings
[FR Doc. 2020–20943 Filed 9–28–20; 8:45 am]
VerDate Sep<11>2014
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the President’s Cancer
Panel.
The meetings will be held as virtual
meetings and are open to the public.
Individuals who plan to view the virtual
meetings and need special assistance or
other reasonable accommodations to
view the meetings should notify the
Contact Person listed below in advance
of the meetings. The meetings can be
accessed by clicking on the following
link: https://nci.rev.vbrick.com/#/
webcasts/presidentscancerpanel.
Name of Committee: President’s Cancer
Panel.
Date: November 2, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: Improving Resilience and Equity
in Cancer Screening: Lessons from COVID–19
and Beyond (Day 1—Colorectal Cancer).
Place: National Cancer Institute, 31 Center
Drive, Building 31, Room 11A48, Rockville,
MD 20850, (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH, 31
Center Drive, Room 11A48 MSC 2590,
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Name of Committee: President’s Cancer
Panel.
Date: November 4, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: Improving Resilience and Equity
in Cancer Screening: Lessons from COVID–19
and Beyond (Day 2—Colorectal Cancer).
Place: National Cancer Institute, 31 Center
Drive, Building 31, Room 11A48, Rockville,
MD 20850 (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
61017
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH, 31
Center Drive, Room 11A48 MSC 2590,
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Name of Committee: President’s Cancer
Panel.
Date: November 9, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: Improving Resilience and Equity
in Cancer Screening: Lessons from COVID–19
and Beyond (Day 1—Cervical Cancer).
Place: National Cancer Institute, 31 Center
Drive, Building 31, Room 11A48, Rockville,
MD 20850, (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH, 31
Center Drive, Room 11A48 MSC 2590,
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Name of Committee: President’s Cancer
Panel.
Date: November 10, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: Improving Resilience and Equity
in Cancer Screening: Lessons from COVID–19
and Beyond (Day 2—Cervical Cancer).
Place: National Cancer Institute, 31 Center
Drive, Building 31, Room 11A48, Rockville,
MD, 20850 (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH, 31
Center Drive, Room 11A48 MSC 2590
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Name of Committee: President’s Cancer
Panel.
Date: November 16, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: Improving Resilience and Equity
in Cancer Screening: Lessons from COVID–19
and Beyond (Day 1—Breast Cancer).
Place: National Cancer Institute, 31 Center
Drive, Building 31, Room 11A48, Rockville,
MD 20850, (Virtual Meeting).
Access to Meeting: https://
nci.rev.vbrick.com/#/webcasts/
presidentscancerpanel.
Contact Person: Maureen R. Johnson,
Ph.D., Executive Secretary, President’s
Cancer Panel, Special Assistant to the
Director, National Cancer Institute, NIH, 31
Center Drive, Room 11A48, MSC 2590,
Bethesda, MD 20892, 240–781–3327,
johnsonr@mail.nih.gov.
Name of Committee: President’s Cancer
Panel.
Date: November 18, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: Improving Resilience and Equity
in Cancer Screening: Lessons from COVID–19
and Beyond (Day 2—Breast Cancer).
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 85, Number 189 (Tuesday, September 29, 2020)]
[Notices]
[Pages 61016-61017]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-20943]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Meeting of the CDC/HRSA Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and Treatment
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, this
notice announces that the Centers for Disease Control and Prevention
(CDC)/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment (CHAC) has scheduled a public meeting.
DATES: November 5, 2020, 2:00 p.m.-5:15 p.m. Eastern Time (ET) and
November 6, 2020, 2:00 p.m.-5:15 p.m. ET. The deadline for online
registration is 12:00 p.m. ET on November 2, 2020.
ADDRESSES: This meeting will be held virtually. Please visit the
meeting information page to register: https://chacfall2020.org.
FOR FURTHER INFORMATION CONTACT: Theresa Jumento, Senior Public Health
Advisor, HIV/AIDS Bureau, HRSA, 5600 Fishers Lane, Rockville, Maryland
20857; 301-443-5807; or [email protected].
SUPPLEMENTARY INFORMATION: CHAC was established under section 222 of
the Public Health Service Act, [42 U.S.C. 217a], as amended.
The purpose of CHAC is to advise the Secretary, HHS; the Director,
CDC; and the Administrator, HRSA regarding objectives, strategies,
policies, and priorities for HIV, viral hepatitis, and other STDs;
prevention and treatment efforts including surveillance of HIV
infection, viral hepatitis, and other STDs, and related behaviors;
epidemiologic, behavioral, health services, and laboratory research on
HIV, viral hepatitis, and other STDs; identification of policy issues
related to HIV/viral hepatitis/STD professional eduction, patient
healthcare delivery, and prevention services; agency policies about
prevention of HIV, viral hepatitis and other STDs; treatment,
healthcare delivery, and research and training; strategic issues
influencing the ability of CDC and HRSA to fulfill their missions of
providing prevention and treatment services; programmatic efforts to
prevent and treat HIV, viral hepatitis, and other STDs; and support to
the agencies in their developoment of responses to emerging health
needs related to HIV, viral hepatitis, and other STDs.
During the November 5-6, 2020, meeting, CHAC will discuss community
engagement activities related to the President's initiative on ``Ending
the HIV Epidemic: A Plan for America'' and the COVID-19 pandemic. CHAC
will also discuss the needs and challenges of HIV prevention and care
for women. Agenda items are subject to change as priorities dictate.
Refer to the CHAC meeting information page for any updated information
concerning the meeting.
While this meeting is open to the public, advance registration is
required. Members of the public will have the opportunity to provide
comments. Requests to offer oral comments will be accepted in the order
they are received and may be limited as time allows.
[[Page 61017]]
Public participants may also submit written statements as further
described below. To submit written comments or to request time for an
oral comment at the meeting, please register online by 12:00 p.m. ET on
October 28, 2020.
Information about CHAC can be found on the CHAC website at https://www.cdc.gov/maso/facm/facmCHACHSPT.html. Visit the meeting information
page for additional details https://chacfall2020.org. Individuals who
plan to attend and need special assistance or another reasonable
accommodation should notify Theresa Jumento at the email address and
phone number listed above at least 10 business days prior to the
meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2020-20943 Filed 9-28-20; 8:45 am]
BILLING CODE 4165-15-P
